ARTICLE | Clinical News
FDA lifts partial hold on Aduro's candidates
November 21, 2016 11:59 PM UTC
Aduro Biotech Inc. (NASDAQ:ADRO) said FDA lifted a partial clinical hold on trials evaluating candidates developed using the company's Listeria monocytogenes-based immunotherapy construct (LADD) platform. The studies may resume enrollment. Patients in the trials had continued to receive treatment.
The agency placed the hold last month after a blood culture sample from a pancreatic cancer patient in Aduro’s Phase IIb ECLIPSE trial of LADD-based vaccine CRS-207 tested positive for Listeria several months after treatment (see BioCentury Extra, Oct. 24)...
BCIQ Company Profiles
BCIQ Target Profiles